Patent intelligence · US
US 11802292
Modified orthopoxvirus vectors
Modified orthopoxvirus vectors
Patent details — US 11802292
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 31, 2023
- Expiration
- Oct 26, 2043
- Applicant
- TURNSTONE BIOLOGICS CORP.
- Claims
- 50
- CPC classes
- A61K, A61K35/768
Quick answer
US 11802292 (Modified orthopoxvirus vectors) is held by TURNSTONE BIOLOGICS CORP.. Status: granted. Granted Oct 31, 2023. Expires Oct 26, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TURNSTONE BIOLOGICS CORP.
- Grant date
- Expiration
- Claims
- 50
- CPC classes
- A61K, A61K35/768
More from TURNSTONE BIOLOGICS CORP.
Related pharmaceutical patents in our USPTO index.
-
US 12310968
Chiral diaryl macrocycles and uses thereof
granted -
US 12252488
HPK1 antagonists and uses thereof
granted -
US 12215105
HPK1 antagonists and uses thereof
granted -
US 12187739
Diaryl macrocycle polymorph
granted -
US 12071442
Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
granted -
US 11981684
Macrocyclic compounds and uses thereof
granted -
US 11926625
HPK1 antagonists and uses thereof
granted
Frequently asked questions
What is US patent 11802292?
US 11802292 (Modified orthopoxvirus vectors) is held by TURNSTONE BIOLOGICS CORP.. Status: granted. Granted Oct 31, 2023. Expires Oct 26, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11802292?
TURNSTONE BIOLOGICS CORP. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 40 pharmaceutical patents for this assignee.
When does US 11802292 expire?
Our index shows an expiration date of Oct 26, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.